NCT02350881

Brief Summary

Foot silicone implants suffer from bad reputation on the market, due to poor results obtained with the first generations of implants. Allergies to silicone, infections due to silicone and implants breakage used to be common with previous generations of silicone implants. Publications relative to those implants showed that the survival rates after 5 years of follow-up were unsatisfactory. Since 1998, Tornier has been selling a new generation of silicone implants made of Ultrasil™. The use of this new material in its manufacturing process together with its innovative geometry, make the Primus™ FGT a much more resistant, anatomic and long lasting implant. The main objective of this study is to evaluate the clinical outcomes of the implantation of Primus™ FGT implant in great toe arthroplasty. The study will capture long term outcomes in terms of functional metrics from documented clinical data. Other objectives are to evaluate the outcomes in terms of radiological evaluation and of safety during all the follow-up.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2013

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2013

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2014

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

January 19, 2015

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 30, 2015

Completed
1.8 years until next milestone

Results Posted

Study results publicly available

October 31, 2016

Completed
Last Updated

October 31, 2016

Status Verified

May 1, 2016

Enrollment Period

1.1 years

First QC Date

January 19, 2015

Results QC Date

May 2, 2016

Last Update Submit

September 12, 2016

Conditions

Outcome Measures

Primary Outcomes (7)

  • AOFAS Hallux-MTP-IP Score - Overall

    AOFAS (American Orthopedic Foot and Ankle Society) Hallux-MTP-IP (Hallux-Meta-Tarso-Phalangeal-Inter-Phalangeal) score is composed of 3 sub-scores : (i) Pain score is ranging from 0 to 40 points ; Function score is ranging from 0 to 45 points ; Alignment is ranging from 0 to 15 points. The AOFAS total score is then ranging from 0 to 100 points. A result over 80 points is considered "good", below 20 points as "bad".

    mean 6.9 years follow-up (range 5.2 - 9.5)

  • AOFAS Hallux-MTP-IP - PAIN Score

    Pain is a sub-score of the AOFAS Hallux-MTP-IP score and is measured on a scale of 40 points - the higher value represents a minimal pain.

    mean follow-up of 6.9 years (range, 5.2 - 9.5)

  • Pain at Passive Motion of MTP1

    Number of patients reporting pain at passive motion of MTP1 at preoperative and postoperative visits.

    mean follow-up of 6.9 years (range, 5.2 - 9.5)

  • Pain at Pressure of MTP1

    Number of patients reporting pain at pressure of MTP1 at preoperative and postoperative visits.

    mean follow-up of 6.9 years (range, 5.2 - 9.5)

  • Walking Perimeter

    Subjective evaluation by the patients of their walking perimeter, postoperatively versus preoperatively. Patient had to choose among 3 variables : "improved", "same", "worsened".

    mean follow-up of 6.9 years (range, 5.2 - 9.5)

  • Pain During Walking

    Subjective evaluation by patients about pain during walking, postoperatively versus preoperatively. Patients had to choose among 4 variables : "disappeared", "less", same", "greater".

    mean follow-up of 6.9 years (range, 5.2 - 9.5)

  • Pain at Rest

    Subjective evaluation of patients about ther pain at rest, postoperatively versus preoperatively. Patients had to choose among 4 variables : "disappeared", "less", "same, "greater".

    mean follow-up of 6.9 years (range, 5.2 - 9.5)

Secondary Outcomes (3)

  • Osteolysis

    mean 6.9 years (range, 5.5 - 9.5)

  • Bone Resorption

    mean 6.9 years (range, 5.5 - 9.5)

  • Survival of the Implant.

    mean follow-up of 6.9 years (range, 5.2 - 9.5)

Interventions

Great toe arthroplasty consists of replacing the first Meta-Tarso-Phalangeal (MTP1) joint by a two hinged prosthesis made of silicone : the Primus FGT implant (FGTI). The Primus is designed with an axially offset hinge to align with the anatomy of the MTP joint. This results in less implant stresses and improved toe function.

Also known as: First metatarsophalangeal arthroplasty

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study has included all patients who had had a Primus™ FGT implantation.

You may qualify if:

  • patient has had a Primus™ FGT implantation for one of the following indications: hallux limitus, hallux rigidus, hallux abducto valgus associated with severe arthritis, unstable or painful joint from previous surgery on the great toe,
  • patient having all necessary clinical and radiographical data available.,
  • patient has been informed about this scientific study and has provided their Consent to participate.

You may not qualify if:

  • patient does not have clinical and radiographic follow-up data available.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Casa Di Cura Villa Berica

Vicenza, Vicenza, 36100, Italy

Location

MeSH Terms

Conditions

Arthritis, RheumatoidOsteoarthritisBunion

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System DiseasesFoot Deformities, AcquiredFoot Deformities

Limitations and Caveats

* inclusion of patients from only 1 site, operated by a single surgeon * lack of control group for comparison with another treatment option * inability to compare preoperative and postoperative AOFAS scores

Results Point of Contact

Title
Dr Stefano Fieschi
Organization
Casa di Cura VIlla Berica

Study Officials

  • Stefano FIESCHI, MD

    Casa di Cura Villa Berica - Vicenza - Italy

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
observational
Observational Model
COHORT
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 19, 2015

First Posted

January 30, 2015

Study Start

May 1, 2013

Primary Completion

June 1, 2014

Study Completion

November 1, 2014

Last Updated

October 31, 2016

Results First Posted

October 31, 2016

Record last verified: 2016-05

Locations